Proteostasis Therapeutics (NASDAQ: PTI) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.
Volatility and Risk
Proteostasis Therapeutics has a beta of 9.95, indicating that its stock price is 895% more volatile than the S&P 500. Comparatively, Xencor has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Proteostasis Therapeutics and Xencor, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Proteostasis Therapeutics currently has a consensus price target of $12.33, suggesting a potential upside of 670.83%. Xencor has a consensus price target of $30.25, suggesting a potential upside of 49.09%. Given Proteostasis Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Proteostasis Therapeutics is more favorable than Xencor.
Valuation and Earnings
This table compares Proteostasis Therapeutics and Xencor’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Proteostasis Therapeutics||$8.38 million||4.78||-$37.23 million||($2.20)||-0.73|
|Xencor||$87.52 million||10.89||$23.62 million||($1.01)||-20.09|
Xencor has higher revenue and earnings than Proteostasis Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Proteostasis Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
73.7% of Proteostasis Therapeutics shares are held by institutional investors. Comparatively, 76.7% of Xencor shares are held by institutional investors. 17.4% of Proteostasis Therapeutics shares are held by company insiders. Comparatively, 4.1% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Proteostasis Therapeutics and Xencor’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Xencor beats Proteostasis Therapeutics on 8 of the 12 factors compared between the two stocks.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.
Xencor Company Profile
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
Receive News & Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.